Skip to content
DataLookout
Menu

BRIGHT LIGHTNCT07923019

BRIGHT-LIGHT: Studying Red Light Therapy for Severe Short-Sightedness or Short-Sightedness That Worsens Despite Standard Treatment

StatusNot Yet Recruiting
PhaseNot applicable
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Eligibility criteria expanded, about 13 words
  2. Study First Submitted
  • Minor: routine updates

Endpoints

Primary

Change in Best-Corrected Visual Acuity
Timeframe: Baseline to 12 months, with assessments at 1, 3, 6 and 12 months.
Occurrence of Retinal Structural Abnormalities
Timeframe: Throughout the 12-month study period.
Occurrence of Retinal Functional Abnormalities
Timeframe: Throughout the 12-month study period.

Secondary (5)

Proportion of Participants Achieving Effective Myopia Control
Change in Axial Length
Change in Spherical Equivalent Refraction
Change in Choroidal Thickness
Change in Retinal Function

Arms and interventions

Repeated Low-Level Red-Light (RLRL) TherapyExperimental

Participants will receive repeated low-level red-light (RLRL) therapy using the Eyerising Myopia Management Device for 12 months. Each session lasts 3 minutes, with two sessions per treatment day separated by at least 4 hours, up to 10 sessions per week. Participants using myopia-control spectacles or multifocal contact lenses may continue these treatments alongside RLRL or discontinue them and switch to RLRL alone. Participants receiving atropine eye drops must discontinue atropine before starting RLRL.

Conventional Myopia ManagementActive comparator

Participants will continue conventional myopia-control treatment, such as atropine eye drops, myopia-control spectacles or multifocal contact lenses, without RLRL therapy. This concurrent control group will undergo study assessments over 12 months to allow comparison of safety findings and myopia progression with the RLRL group.

Devices: Repeated low-level red-light (RLRL) therapy

Other: Continued existing myopia treatment strategy

Sites

2 sites in 1 country